Last reviewed · How we verify

NCT06777290

Comparison of Whole-body MRI, Circulating DNA and PET-CT in Staging, Prognosis, and Treatment Response in Patients with Diffuse Large Cell B Lymphoma

Completed Last updated 15 January 2025
What this trial tests

trial in Lymphoma, Diffuse Large B-Cell in 14 participants. Completed in 31 December 2022.

Timeline
1 January 2021
Primary endpoint
31 December 2022
31 December 2022

Quick facts

Lead sponsorCharles University, Czech Republic
StatusCompleted
Study typeOBSERVATIONAL
Enrollment14
Start date1 January 2021
Primary completion31 December 2022
Estimated completion31 December 2022
Sites1 location across Czechia

Conditions studied

Sponsor

Charles University, Czech Republic

Who can join

18 and older, any sex, with Lymphoma, Diffuse Large B-Cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to compare the diagnostic performance of whole-body MRI scan, positron emission tomography + CT, and circulating tumor DNA in patients with hematologic malignancy called diffuse large cell B lymphoma (DLBCL) in staging and restaging, and prognosis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Liquid Biopsy in B and T Cell Lymphomas: From Bench to Bedside.
    Almasri M, Maher N, Al Deeban B, Diop NM, et al · · 2025 · cited 9× · PMID 40430009 · DOI 10.3390/ijms26104869

Verify or expand the search:

Other Charles University, Czech Republic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06777290.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing